Biological Dynamics, Inc., a company commercializing its exosome-isolation ExoVerita™ platform for early disease surveillance and other applications, today announced completion of the analytical and clinical validation of its lab developed test (LDT), ExoVita™ Pancreas in the company’s CLIA certified and CAP accredited laboratory.
Read MoreBiological Dynamics, a company developing and commercializing its ExoVeritaTM platform for early disease diagnostics, announced today that Harmeet Dhani, MD, MSc, Medical Director will present at the Precision Medicine World Conference (PMWC) in Santa Clara, Calif.
Dr. Dhani’s PMWC showcase presentation on January 26th is part of the Clinical Utility of Liquid Biopsies track. The track focuses on how liquid biopsy technologies facilitate detection of early-stage cancer, which could help contribute to improving patient outcomes rates and reduce the need for invasive diagnostic procedures.
Biological Dynamics’ ExoVerita platform targets extracellular vesicles in blood, isolating exosomes to detect biomarkers of early-stage cancers. Its first product is an assay for pancreatic ductal adenocarcinoma (PDAC) assay that identifies exosomal PDAC-associated protein biomarkers, detecting Stage 1 and 2 pancreatic cancers with high sensitivity, a key advantage of the technology. Dr. Dhani’s presentation will discuss the implication of exosomes, the ExoVerita technology platform, review a subject case study, and provide an overview of the preliminary data in multi-cancer early detection and the ExoLuminate registry trial (NCT05625529) which enrolled its first subject in December.
“Leveraging the innovations of our ExoVerita platform, we are developing solutions for patients, their families and the medical community. We believe our decade of expertise in isolating exosomes will significantly improve a patient’s diagnostic journey, including with future clinical applications for multiple cancers,” noted Dr. Dhani.
Dr. Dhani is a surgeon scientist with a background in abdominal transplant and hepato-pancreato-biliary (HPB) surgery. He also holds a Master’s in Clinical Research from UCSD and anticipates completing his MBA from Georgetown University in 2025.
About Biological Dynamics
Biological Dynamics, Inc. is committed to improving global health outcomes by detecting diseases at the earliest stages. The company's proprietary ExoVerita™ platform simplifies isolation of extracellular vesicles, enabling multiomic applications. Its PDAC test operates in a College of American Pathologists (CAP) accredited, CLIA-certified clinical laboratory in San Diego. Biological Dynamics recently announced the initiation of the ExoLuminate study, a clinical trial to demonstrate effectiveness of early-stage detection of pancreatic cancer. Learn more at www.ExoLuminate.com.
To learn more about the application of exosome-isolation technology for the detection of Stage 1 and 2 cancers, visit Biological Dynamics in booth D3526.
Disclaimer: Biological Dynamics does not provide any diagnostic results for patients and has no authority, responsibility, or liability with respect to any clinical decisions made by – or in connection with – a provider. Nothing herein and no aspect of any engagement between Biological Dynamics and its collaborating institutions is intended – or shall be deemed – to subordinate, usurp, or otherwise diminish any providers’ sole authority and discretion with respect to all clinical decision-making for its patients.
Biological Dynamics, a company developing its exosome-isolation ExoVerita™ platform for early disease diagnostics, announced today that its Director of Medical Affairs, Harmeet Dhani, MD, MSc, will speak at the inaugural PRECEDE Early Detection Biomarker Summit in New York.
Read MoreBiological Dynamics is a private molecular diagnostics company located in San Diego. Our proprietary technology offers a novel, fast, and cost-effective lab-on-chip ACE platform that isolates nanoparticles from high conductance physiological solutions.
Our product, the TR(ACE)™ assay, will utilize the platform for monitoring treatment response in oncology. TR(ACE)™ has not been cleared or approved by the U.S. FDA or any foreign regulatory agency.
